Skip to main
AXSM

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 44%
Buy 50%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics Inc. exhibits a strong positive outlook due to the 8% quarter-over-quarter growth in prescriptions for Auvelity, bolstered by a direct-to-consumer campaign that is expected to sustain momentum through 2026. The company is preparing to scale its operations significantly, with an expanded sales force projected to enhance market penetration and drive towards a $1.6 billion sales opportunity in the upcoming years, particularly in the context of the anticipated launch of AXS-05 for Alzheimer's Disease. Additionally, Axsome's advancing pipeline and potential for achieving cash flow-positive status prior to mid-2026 further reinforce its growth prospects and overall market position within the central nervous system disorder therapeutics sector.

Bears say

Axsome Therapeutics Inc. faces substantial risks that contribute to a negative outlook on its stock, primarily tied to potential setbacks in its clinical trials and regulatory hurdles for its pipeline drugs, such as AXS-05 and AXS-12. The company may encounter challenges with market access for its product AUVELITY, and competition within a crowded market could hinder its commercial success, leading to lower-than-expected revenue projections. Additionally, there are concerns regarding the financial sustainability of ongoing operations given the significant expenditures on research and development alongside the risk of dilution and inability to secure timely approvals for its therapies.

Axsome Therapeutics (AXSM) has been analyzed by 16 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 50% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 16 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $211.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $211.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.